24.26

3.31% -0.83

After Hours: 23.30 -0.96 -3.96%

Kailera Therapeutics Inc (KLRA)

Overview News Price History Discussions Forecast

Kailera Therapeutics Inc stock is traded at $24.26, with a volume of 425.20K. It is down -3.31% in the last 24 hours and up +0.00% over the past month. Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Previous Close:

$25.09

Open:

$25.01

24h Volume:

425.20K

Relative Volume:

2.22

Market Cap:

$3.14B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+1.85%

1M Performance:

+0.00%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$23.80

$25.50

1-Week Range:

$23.28

$25.55

52-Week Range:

$20.86

$28.23

Kailera Therapeutics Inc Stock (KLRA) Company Profile

Name

Kailera Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

Address

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

KLRA's Discussions on Twitter

Compare KLRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KLRA Kailera Therapeutics Inc	24.26	3.25B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Kailera Therapeutics Inc Stock (KLRA) Latest News

May 04, 2026

Kailera Therapeutics debut marks largest biotech IPO since 2021 amid weight loss race - MSN

May 04, 2026

Kailera IPO And Governance Overhaul Set Terms For NASDAQ Composite Debut - Yahoo Finance

May 01, 2026

GLP-1 developer Kailera prices IPO at $16 per share to raise $625M - MSN

May 01, 2026

KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC

May 01, 2026

Apr 29, 2026

Kailera Therapeutics (KLRA) Stock Price, News & Analysis $KLRA - MarketBeat

Apr 29, 2026

What is the current Price Target and Forecast for Kailera Therapeutics, Inc. (KLRA) - Zacks Investment Research

Apr 29, 2026

Apr 28, 2026

Obesity drugmaker Kailera soars 63% after $625 million IPO - MSN

Apr 28, 2026

Obesity treatment firm Kailera upsizes IPO to raise $625 million - MSN

Apr 28, 2026

KLRA Price History for Kailera Therapeutics Stock - Barchart

Apr 28, 2026

Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. - BioPharma Dive

Apr 28, 2026

Apr 27, 2026

KLRA SEC FilingsKailera Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 27, 2026

KLRA Insider Trading (Kailera Therapeutics, Inc. stock) - StockInvest.us

Apr 27, 2026

GLP-1 developer Kailera, proteomics firm Alamar file for US IPOs - MSN

Apr 27, 2026

A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Million - The Motley Fool

Apr 27, 2026

Apr 26, 2026

Weight loss drug developer Kailera climbs 50% on trading debut - MSN

Apr 26, 2026

Apr 25, 2026

KLRA (Kailera Therapeutics) PB Ratio : (As of Apr. 25, 2026) - GuruFocus

Apr 25, 2026

Apr 24, 2026

Life science firms seek $693 million in US IPOs as pace picks up - MSN

Apr 24, 2026

Kailera Therapeutics IPO Debut And Index Inclusion Spur Early Assessment - Sahm

Apr 24, 2026

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy - Sahm

Apr 24, 2026

IPO Tracker 2026: Avalyn seeks public debut to support new lung drug formulations - BioSpace

Apr 24, 2026

Apr 23, 2026

Bain Capital Life Sciences Secures Board Role at Kailera Therapeutics with 17.4% Stake - TradingView

Apr 23, 2026

BCPE Perseus Investor Takes Activist Stake at Kailera Therapeutics with 20.3% Stake - TradingView

Apr 23, 2026

Bain Capital entity holds 20.3% of Kailera (KLRA) after IPO - Stock Titan

Apr 23, 2026

Apr 22, 2026

RTW-managed funds lift Kailera Therapeutics (KLRA) stake via buys, conversions - Stock Titan

Apr 22, 2026

KLRA: Kailera Therapeutics, Inc.Brokerage Recommendations Chart - Zacks Investment Research

Apr 22, 2026

Kailera Therapeutics (KLRA) holder converts Series A-2 preferred into common - Stock Titan

Apr 22, 2026

The 5 largest IPOs in biopharma history - BioSpace

Apr 22, 2026

Apr 21, 2026

Total revenue of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView

Apr 21, 2026

Number of employees of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView

Apr 21, 2026

Kailera Therapeutics, Inc. Revenue Breakdown – NASDAQ:KLRA - TradingView

Apr 21, 2026